Vaxcyte (PCVX) announced the initiation of the Phase 2 study of VAX-31 in healthy infants and that the first study participants have been dosed. This study is evaluating the safety, tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine, PCV, candidate designed to prevent invasive pneumococcal disease, IPD. The Company expects to share topline data from the primary three-dose immunization series of the study in mid-2026, followed by topline data from the booster dose approximately nine months later.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX:
- Trump expected to pick Martin Makary to head FDA, Reuters reports
- Vaccine makers fall after Trump nominates RFK to head HHS
- Vaxcyte provides regulatory updates on VAX-31 programs
- Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
- Vaxcyte Reports Progress and Strengthens Financial Position